The expanding role of H₁ antihistamines: a patent survey of selective and dual activity compounds 2005 – 2010

Bibliography

• Akdis CA, Blaser K. Histamine in the immune regulation of allergic inflammation. J Allergy Clin Immunol 2003;112(1):15-22
   Google Scholar
• Berger WE. Overview of allergic rhinitis. Ann Allergy Asthma Immunol 2003;90:7-12
   PubMed Web of Science ®Google Scholar
• Bousquet J, van Cauwenberge P, Khaltaev N, ; In collaboration with the World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(5):S147-334
   Google Scholar
• Raffa RB. Antihistamines as analgesics. J Clin Pharm Ther 2001;26:81-5
   Google Scholar
• Lin J-S, Hou Y, Sakai K, Jouvet M. Histamine descending inputs to the Mesopontine Tegmentum and their role in the cortical activation and wakefulness in the cat. J Neurosci 1996;16:1523-37
   PubMed Web of Science ®Google Scholar
• Togias A. H1-receptors: localization and role in airway physiology and in immune functions. J Allergy Clin Immunol 2003;112(4):S60-8
   Google Scholar
• Simons FE. H1-antihistamines: more relevant than ever in the treatment of allergic disorders. J Allergy Clin Immunol 2003;112(4):S42-52
   Google Scholar
• Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 2008;7:41-53
   PubMed Web of Science ®Google Scholar
• Bakker RA, Timmerman H, Leurs R. Histamine receptors: specific ligands, receptor biochemistry, and signal transduction. Clin Allery Immunol 2002;17:27-64
   PubMedGoogle Scholar
• Moniri NH, Covington-Strachan D, Booth RG. Ligand-directed functional heterogeneity of histamine H1 receptors: novel dual-function ligands selectively activate and block H1-mediated phospholipase C and adenylyl cyclase signaling. J Pharmacol Exp Ther 2004;311:274-81
   Google Scholar
• Bakker RA, Wieland K, Timmerman H, Leurs R. Constitutive activity of the histamine H1 receptor reveals inverse agonism of histamine H1 receptor antagonists. Eur J Pharmacol 2000;387(1):R5-7
   Google Scholar
• Staub AM, Bovet D. Actions de la thymoethyl-diethylamine (929F) et des ethers phenoliques sur le chocanaphylactique de cobaye. CR Soc Biol 1937;128:818-25
   Google Scholar
• Meolie AL, Rosen C, Kristo D, Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence. J Clin Sleep Med 2005;1:173-87
   PubMed Web of Science ®Google Scholar
• Kim J-H, Park S-H, Moon YW, Histamine H1 receptor induces cytosolic calcium increase and aquaporin translocation in human salivary gland cells. JPET 2009;330:403-12
   PubMed Web of Science ®Google Scholar
• Van-Cauwenberge P, Bachert C, Passalacqua G, Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000;55(2):116-34
   Google Scholar
• Dubuske LM. Second-generation antihistamines: the risk of ventricular arrhythmias. Clin Ther 1999;21(2):281-95
   Google Scholar
• Suessbrich H, Waldegger S, Lang F, Busch AE. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett 1996;385(1-2):77-80
   Google Scholar
• Renwick AG. The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Clin Exp Allergy 1999;29(Suppl 3):116-24
   PubMedGoogle Scholar
• Holgate ST, Canonica GW, Simons FE, Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003;33(9):1305-24
   Google Scholar
• Singh-Franco D, Ghin HL, Robles GI, Levocetirizine for the treatment of allergic rhinitis and chronic idiopathic urticaria in adults and children. Clin Ther 2009;31(8):1664-87
   Google Scholar
• Kalogeromitros D, Kempuraj D, Katsarou-Katsari A, Theophylline as ‘add-on’ therapy to cetirizine in patients with chronic idiopathic urticaria. A randomized, double-blind, placebo-controlled pilot study. Int Arch Allergy Immunol 2006;139(3):258-64
   Google Scholar
• Aslanian R, Mutahi MW, Shih N-Y, Identification of a dual histamine H1/H3 receptor ligand based on the H1 antagonist chlorpheniramine. Bioorg Med Chem Lett 2003;13:1959-61
   PubMed Web of Science ®Google Scholar
• McLeod RL, Mingo GG, Kreutner W, Hey JA. Effect of combined histamine H1 and H3 receptor blockade on cutaneous microvascular permeability elicited by compound 48/80. Life Sci 2005;76:1787-94
   PubMed Web of Science ®Google Scholar
• Giannaras A, Selig W, Ellis J, Hullinger T. The effect of a novel, dual function histamine H1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasation. Eur J Pharmacol 2005;506:265-71
   PubMed Web of Science ®Google Scholar
• Arias K, Baig M, Colangelo M, Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions. J Allergy Clin Immunol 2009;124(2):307-14
   Google Scholar
• Suzuki K, Morokata T, Morihira K, A dual antagonist for chemokine CCR3 receptor and histamine H1 receptor. Eur J Pharmacol 2007;563:224-32
   PubMed Web of Science ®Google Scholar
• Greiff L, Ahlstrom-Emanuelsson C, Bahl A, Effects of a dual CCR3 and H1-antagonist on symptoms and eosinophilic inflammation in allergic rhinitis. Respir Res 2010;11:17
   Google Scholar
• Scannell RT, Differding E, Talaga P. Dual acting antihistaminergic agents. Mini Rev Med Chem 2004;4:923-33
   PubMed Web of Science ®Google Scholar
• Deml KF, Beermann S, Neumann D, Interactions of histamine H1-receptor agonists and antagonists with the human histamine H4-receptor. Mol Pharmacol 2009;76(5):1019-30
   Google Scholar
• Metz M, Scholz E, Ferran M, Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol 2010;104:86-92
   PubMed Web of Science ®Google Scholar
• Brockman HL, Momsen MM, Knudtson JR, Interactions of olopatadine and selected antihistamines with model and natural membranes. Ocul Immunol Inflamm 2003;11:247-68
   PubMed Web of Science ®Google Scholar
• Leonardi A, Quintieri L. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. Expert Opin Pharmacol 2010;11:969-81
   PubMed Web of Science ®Google Scholar
• Kida T, Fujii A, Sakai O, Bepotastine besilate, a highly selective histamine H1 receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models. Exp Eye Res 2010;91:85-91
   PubMed Web of Science ®Google Scholar
• Roth T, Rogowski R, Hull S, Efficacy and safety of doxepin 1mg, 3mg, and 6mg in adults with primary insomnia. Sleep 2007;30:1555-61
   PubMed Web of Science ®Google Scholar
• Moree WJ, Li B-F, Jovic F, Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia. J Med Chem 2009;52:5307-10
   Google Scholar
• Madan A, O'Brien Z, Wen J, A pharmacokinetic evaluation of five H1 antagonists after an oral and intravenous microdose to human subjects. Br J Clin Pharmacol 2009;67:288-98
   PubMed Web of Science ®Google Scholar
• Hall H, Sallemark M, Wedel I. Acute effects of atypical antidepressants on various receptors in the rat brain. Acta Pharmacol Toxicol 1984;54:379-84
   Google Scholar
• Teegarden BR, Shamma HA, Xiong Y. 5-HT2A inverse agonists for the treatment of insomnia. Curr Top Med Chem 2008;8:969-76
   PubMed Web of Science ®Google Scholar
• Mobarakeh JI, Sakurada S, Katsuyama S, Role of histamine H1 receptor in pain perception: a study of the receptor gene knockout mice. Eur J Pharmacol 2000;391:81-9
   PubMed Web of Science ®Google Scholar
• Olsen UB, Eltorp CT, Ingvardsen BK, ReN 1869, a novel tricyclic antihistamine, is active against neurogenic pain and inflammation. Eur J Pharmacol 2002;435:43-57
   Google Scholar
• Dray A. Novel molecular targets in pain control. Curr Opin Anaesthesiol 2003;16:521-5
   PubMed Web of Science ®Google Scholar
• Erfanparast A, Tamaddonfard E, Farshid AA, Khalilzadeh E. Effect of microinjection of histamine into the dorsal hippocampus on the orofacial formalin-induced pain in rats. Eur J Pharmacol 2010;627:119-23
   PubMed Web of Science ®Google Scholar
• Tiligada E, Zampeli E, Sander K, Histamine H3 and H4 receptors as novel drug targets. Expert Opin Invest Drugs 2009;18:1519-31
   PubMed Web of Science ®Google Scholar
• Liu H, Altenbach RJ, Carr TL, cis-4-(Piperazin-1-yl)-5,6,7a,8,9, 10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia. J Med Chem 2008;51:7094-8
   PubMed Web of Science ®Google Scholar
• Hasanein P. Two histamine H2 receptor antagonists, zolantidine and cimetidine, modulate nociception in cholestatic rats. J Psychopharmacol 2009; doi:10.1177/0269881109106912
   Google Scholar
• Chong CR, Chen X, Shi L, A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol 2006;2:415-16
   PubMed Web of Science ®Google Scholar
• Musonda CC, Whitlock GA, Witty MJ, Chloroquine-astemizole hybrids with potent in vitro and in vivo antiplasmodial activity. Bioorg Med Chem Lett 2009;19:481-4
   Google Scholar
• Elan Pharma Int. Nanoparticulate corticosteroid and antihistamine formulations. WO2006102494; 2006
   Google Scholar
• Nektar Therapeutics. Oligomer-antihistamine conjugates. WO2008112257; 2008
   Google Scholar
• Biolipox. Antihistamine- and corticosteroid- containing liposome composition and its use for the manufacture of a medicament for treating rhinitis and related disorders. WO2007026151; 2007
   Google Scholar
• Fonquerna S, Miralpeix M. H1-antihistamines: patent highlights 2000 – 2005. Expert Opin Ther Pat 2006;16:109-17
   Web of Science ®Google Scholar
• Terada N, Hamano N, Kim WJ, The kinetics of allergen-induced eotaxin level in nasal lavage fluid: its key role in eosinophil recruitment in nasal mucosa. Am J Respir Crit Care Med 2001;164:575-9
   PubMedGoogle Scholar
• Humbles AA, Lu B, Friend DS, The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness. Proc Natl Acad Sci USA 2002;99:1479-84
   PubMed Web of Science ®Google Scholar
• Ying S, Meng Q, Zeibecoglou K, Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and non-atopic (intrinsic) asthmatics. J Immunol 1999;163:6321-9
   PubMed Web of Science ®Google Scholar
• Lilly CM, Nakamura H, Belostotsky OI, Eotaxin expression after segmental allergen challenge in subjects with atopic asthma. Am J Respir Crit Care Med 2001;163:1669-75
   PubMedGoogle Scholar
• Willems LI, Ijzerman AP. Small molecule antagonists for chemokine CCR3 receptors. Med Res Rev 2009; doi: 10.1002/med.20181
   Google Scholar
• Novartis. Azetidine derivatives as CCR-3 receptor antagonists. WO2003077907; 2003
   Google Scholar
• Novartis. 1,3-disubstituted azetidine derivatives as CCR-3 receptor antagonists in the treatment of inflammatory and allergic diseases. WO2005026113; 2005
   Google Scholar
• Yamanouchi. Preparation of N-[1-(6-fluoronaphthalen-2-ylmethyl)pyrrolidin-3-yl]urea derivatives as CCR3 inhibitors. WO2003072545; 2003
   Google Scholar
• Yamanouchi. Preparation of (N-pyrrolidinyl)acrylamide derivatives as CCR3 antagonists for treatment of asthma. WO2004022535; 2004
   Google Scholar
• Astrazeneca. Preparation of piperidine derivatives for the treatment of chemokine or H1 mediated disease state. WO2004085423; US2006281726; 2004
   Google Scholar
• Astrazeneca. A preparation of (piperidinylmethyl)piperidine derivatives, useful for the treatment of chemokine mediated diseases. WO2004087659; US2007032523; US2009118513; 2004
   Google Scholar
• Astrazeneca. Piperdine derivatives for the treatment of chemokines mediated disease. WO2005097775; US20080262037; 2005
   Google Scholar
• Astrazeneca. Piperidine derivatives useful as modulators of chemokine receptor activity. WO2003004487; 2003
   Google Scholar
• Astrazeneca. Preparation of pharmaceuticals salts of [1,4] bipiperidine. WO2005044268; US2007276141; 2005
   Google Scholar
• Astrazeneca. Preparation of piperidinylmethylpiperidines for the treatment of chemokine mediated diseases. WO2006126947; US20080275084; 2006
   Google Scholar
• Astrazeneca. Preparation of novel piperidine derivatives for treatment of chemokine mediated diseases. WO2007011293; 2007
   Google Scholar
• Bryan SA, Jose PJ, Topping JR, Responses of leukocytes to chemokines in whole blood and their antagonism by novel CC-chemokine receptor 3 antagonists. Am J Respir Crit Care Med 2002;165:1602-9
   PubMed Web of Science ®Google Scholar
• Astrazeneca. Preparation of piperidine derivatives for the treatment of chemokine mediated diseases. WO2006126948; US20080200505; 2006
   Google Scholar
• Astrazeneca. Preparation of piperidines as chemokine modulators for treatment of asthma and related diseases. WO20050073192; US2007054924; 2005
   Google Scholar
• Astrazeneca. N-(2-hydroxypropyl-1-yl)piperidine derivatives, their synthesis and use as chemokine receptor modulators and histamine H1 receptor antagonists. WO2007114770; US20080108661; 2007
   Google Scholar
• Available from: http://www.astrazeneca.com/_mshost3690701/content/ resources/media/investors/ 2006-business-review-john.pdf [Accessed 22 May 2010]
   Google Scholar
• Taylor JD, Wreggett KA, Olssen H, Sjorbring U. Latest therapies targeting exacerbations in COPD. Drug Discov Today Ther Strateg 2008;5:101-10
   Google Scholar
• Wijtmans M, Leurs R, de Esch I. Histamine H3 receptor ligands break ground in a remarkable plethora of therapeutic areas. Expert Opin Invest Drugs 2007;16:967-85
   PubMed Web of Science ®Google Scholar
• Varty LM, Hey JA. Histamine H3 receptor activation inhibits neurogenic sympathetic vasoconstriction in porcine nasal mucosa. Eur J Pharmacol 2002;452:339-45
   PubMedGoogle Scholar
• Varty LM, Gustafson E, Laverty M, Hey JA. Activation of histamine H3 receptors in human nasal mucosa inhibits sympathetic vasoconstriction. Eur J Pharmacol 2004;484:83-9
   PubMed Web of Science ®Google Scholar
• Mcleod RL, Mingo GG, Herczku C, Combined histamine H1 and H3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion. Am J Rhinol 1999;13:91-399
   Google Scholar
• Taylor-Clark T, Sodha R, Warner B, Foreman J. Histamine receptors that influence blockage of the normal human nasal airway. Br J Pharmacol 2005;144:867-74
   PubMed Web of Science ®Google Scholar
• Available from: http://www.scribd. com/doc/13937992/ GlaxoSmithKline-Drug- RD-Pipeline-Feburary-2009. [Accessed 22 May 2010]
   Google Scholar
• Available from: http://www.gsk.com/financial/pp_pipeline_standard.htm. [Accessed 22 May 2010]
   Google Scholar
• Glaxo Group. Preparation of 1-{4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl}-{[4(methylsulfonyl)phenyl]carbonyl}piperazine or a derivative thereof for use in treating inflammation or allergies. US20060019964; 2006
   Google Scholar
• Glaxo Group. Preparation of piperidine derivative as H1 receptor antagonist for treatment of allergic rhinitis. WO2006125665; US20060293298; 2006
   Google Scholar
• Glaxo Group. 1-{4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl}-4-{[4-(methylsulfonyl)phenyl]carbonyl}piperazine or a derivative thereof. US20060019964; 2006
   Google Scholar
• Glaxo Group. Preparation of 1-{4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl}-4-{[4-(methylsulfonyl)phenyl]carbonyl}piperazine or a derivative thereof for use in treating inflammation or allergies. WO2006090142; 2006
   Google Scholar
• Norman P. A H3 antagonist for treating allergic rhinitis: a development candidate? Glaxo Group Ltd: WO2006090142. Expert Opin Ther Patents 2007;17(4):449-52
   Web of Science ®Google Scholar
• Glaxo Group. Preparation of 3-[4-[[4-[4-[[3-(3,3-dimethyl-1-piperidinyl)propyl]oxy]phenyl]-1-piperidinyl]carbonyl]-1-naphthalenyl]propanoates as histamine H1 and H3 antagonists for the treatment of inflammatory and/or allergic disorders. WO2007071691; US20080312280; 2007
   Google Scholar
• Glaxo Group. Benzylphthalazinone derivatives as histamine- H1 and histamine- H3 antagonists and their preparation, pharmaceutical compositions and use in the treatment of allergic diseases. WO2007122156; US20090105225; US20080039444; 2007
   Google Scholar
• Glaxo Group. Combination of fluticasone furoate with 4-[(4-chlorophenyl)methyl]-2-({(2R)-1-[4-(4-{[3-(hexahydro-1H-azepin-1-yl)propyl]oxy}phenyl)butyl]-2-pyrrolidinyl}methyl)-1(2H)-phthalazinone. WO2009050159; 2009
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00824356 [Accessed 22 May 2010]
   Google Scholar
• Glaxo Group. Phthalazinone derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use in the treatment of allergic rhinitis and/or other diseases. WO2008074803; 2008
   Google Scholar
• Glaxo Group. Preparation of phthalazines and pyrido[3,4-d]pyridazines as histamine H1 receptor antagonists for treatment of inflammatory and allergic diseases. WO2009047336; 2009
   Google Scholar
• Glaxo Group. Pharmaceutical compositions comprising a histamine H1 receptor antagonist for treatment of inflammatory and allergic disorders. WO20090150101; 2009
   Google Scholar
• Glaxo Group. Compounds. US20090270355; 2009
   Google Scholar
• Glaxo Group. Preparation of quinolinyloxypiperidine and pyrrolidine derivatives for the treatment of inflammatory and allergic diseases of the respiratory tract. WO2009021965; 2009
   Google Scholar
• Glaxo Group. Preparation of quinolines as histamine H1 receptor antagonists for treatment of inflammatory and allergic diseases. WO2009050204; 2009
   Google Scholar
• Glaxo Group. Histamine receptor antagonists comprising an azepin core. WO2007135081; 2007
   Google Scholar
• Sumitomo. Preparation of uracil carboxylic acid derivatives as antiallergic agents. JP2007176851; 2007
   Google Scholar
• Kubota K, Kurebayashi H, Miyachi H, Synthesis and structure–activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H1 antagonists. Bioorg Med Chem Lett 2009;19:2766-71
   PubMed Web of Science ®Google Scholar
• Medical and pharmaceutical industry technology and developmental center. Uses of 2-[Piperidinyl] methyl-2,3-dihydroimidazo[1,2-C]quinazolin-(6H)-one for providing analgesic effect, anti-allergic effect and H1 receptor antagonism effect. US2009082373; 2009
   Google Scholar
• Nippon Zoki Pharmaceuticals. Preparation of piperidine derivatives as histamine receptor antagonists. WO2009096080; 2009
   Google Scholar
• Glass J, Lanctot KL, Herrmann N, Sedative hypnotics in older people with insomnia: a meta analysis of risks and benefits. Br Med J 2005;331:1169-75
   PubMed Web of Science ®Google Scholar
• Vermeeren A. Residual effects of hypnotics. CNS Drugs 2004;18:297-328
   PubMed Web of Science ®Google Scholar
• Barbier AJ, Bradbury MJ. Histaminergic control of sleep wake cycles: recent therapeutic advances for sleep and wake disorders. CNS Neurol Disord Drug Targets 2007;6:31-43
   Google Scholar
• Kay GG, Plotkin KE, Quig MB, Sedating effects of AM/PM antihistamine dosing with evening chlorpheniramine and morning terfenadine. Am J Manag Care 1997;3:1843-8
   Web of Science ®Google Scholar
• Van Ruitenbeek P, Vermeeren A, Riedel WJ. Memory in humans is unaffected by central H1-antagonism, while objectively and subjectively measured sedation is increased. Eur Neuropsychopharmacol 2010; doi:10.1016/j.euroneuro.2009.12.003
   Google Scholar
• Kavey. Antidepressant psychotherapeutic agents for treatment of chronic insomnia. US5643897; 1997
   Google Scholar
• Kavey. Doxepin, amitriptyline, trimipramine, and trazodone for treatment of transient and short-term insomnia. US6211229; 2001
   Google Scholar
• Somaxon Pharmaceuticals. Low-dose doxepin for treatment of sleep disorders in elderly patients. WO2007136845; 2007
   Google Scholar
• Somaxon Pharmaceuticals. Methods of using low-dose doxepin for the improvement of sleep. WO2008085567; 2008
   Google Scholar
• Somaxon Pharmaceuticals. Method using low-dose doxepin for the improvement of sleep. US2009042971; 2009
   Google Scholar
• Somaxon Pharmaceuticals. Compositions and methods related to action of low dosages of doxepin on the H1 and 5-HT2A receptors. WO2009137531; 2009
   Google Scholar
• Somaxon Pharmaceuticals. Ultra low dose doxepin and methods of using the same to treat sleep. US2010105614; 2010
   Google Scholar
• Singh H, Becker PM. Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Invest Drugs 2007;16:1295-305
   PubMed Web of Science ®Google Scholar
• Andersohn F, Schade R, Suissa S, Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009;166:591-8
   PubMed Web of Science ®Google Scholar
• Hypnion. Treatment of CNS disorders using CNS target modulators. WO2003032912; 2003
   Google Scholar
• Hypnion. Treatment of CNS disorders using CNS target modulators. US7317026; 2008
   Google Scholar
• Hypnion. Treatment of CNS disorders using CNS target modulators. US7189757; 2007
   Google Scholar
• Wieland K, Ter Laak AM, Smit MJ, Mutational analysis of the antagonist binding site of the histamine H1 receptor. J Biol Chem 1999;274:29994-30000
   PubMed Web of Science ®Google Scholar
• Hypnion. Preparation of doxepin analogs as antihistamines used as sleep modulators. US7524864; 2009
   Google Scholar
• Hypnion. Doxepin analogs and methods of use thereof. US2005143348; 2005
   Google Scholar
• Hypnion. Preparation of doxepin analogs and their use to modulate sleep. US2005171160; 2005
   Google Scholar
• Hypnion. Doxepine analogs and methods of use thereof. WO2005058880; 2005
   Google Scholar
• Hypnion. Doxepin analogs and methods of use thereof. US7326721; 2008
   Google Scholar
• Hypnion. Preparation of doxepin analogs as sleep modulators. US7411069; 2008
   Google Scholar
• Hypnion. Quetiapine analogs for the modulation of sleep. US7563785; 2009
   Google Scholar
• Hypnion. Loxapine analogs for modulating sleep. US7592333; 2009
   Google Scholar
• Hypnion. Olanzapine analogs and methods of use thereof. WO2007022068; 2007
   Google Scholar
• Palomer A, Príncep M, Guglietta A. Recent advances in the treatment of insomnia. Ann Rep Med Chem 2007;42:63-80
   Google Scholar
• Available from: http://www.hypnion.com/about/news.htm [Accessed 22 May 2010]
   Google Scholar
• Bonhaus DW, Bach C, DeSouza A, The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products:comparison with 5-HT2A and 5-HT2c receptors. Br J Pharmacol 1995;115:622-8
   PubMed Web of Science ®Google Scholar
• Available from: http:/investor.lilly.com/pipeline/.cfm [Accessed 22 May 2010]
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00784875 [Accessed 22 May 2010]
   Google Scholar
• Coon T, Moree WJ, Li B-F, Brain-penetrating 2-aminobenzimidazole H1-antihistamines for the treatment of insomnia. Bioorg Med Chem Lett 2009;19:4380-4
   Google Scholar
• Moree WJ, Jovic F, Coon T, Novel benzothiophene H1-antihistamines for the treatment of insomnia. Bioorg Med Chem Lett 2010;20:2316-20
   Google Scholar
• Li B-F, Moree WJ, Yu J, Selectivity profiling of novel indene H1-antihistamines for the treatment of insomnia. Bioorg Med Chem Lett 2010;20:2629-33
   PubMedGoogle Scholar
• Lavrador-Erb K, Ravula SB, Yu J, The discovery and structure–activity relationships of 2-(piperidin-3-yl)-1Hbenzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia. Bioorg Med Chem Lett 2010;20:2916-9
   PubMed Web of Science ®Google Scholar
• Neurocrine Biosciences. Preparation of heterocyclic-substituted indenylalkylamines as histamine H1 binding ligands for inducing sleep. WO2005097093; 2005
   Google Scholar
• Neurocrine Biosciences. Preparation of benzo[b]thiophene H1 receptor antagonists as sleep-inducing compounds. WO2006049497; 2006
   Google Scholar
• Glaxo Group. Spiro compounds useful as antagonists of the H1 receptor and their stereoselective preparation, pharmaceutical compositions and use in the treatment of sleep disorders. WO2009016084; 2009
   Google Scholar
• Glaxo Group. Spiro compounds useful as antagonists of the H1 receptor and their asymmetric preparation, pharmaceutical compositions and use in the treatment of sleep disorders. WO2009016085; 2009
   Google Scholar
• Blaiss MS. Cost-effectiveness of H1-antihistamines. In: Histamine and H1-Antihistamines in allergic disease. Ed. Simons FER. Chapter 10. New York; 2002. p. 319-36
   Google Scholar
• Govoni M, Bakker RA, Van de Wetering I, Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists. J Med Chem 2003;46:5812-24
   PubMed Web of Science ®Google Scholar
• Jordana M, Waserman S, Arias K. Treatment and/or prevention of peanut induced anaphylaxis. WO2010020057; 2010
   Google Scholar